Inflammatory diseases of the skin such as psoriasis, atopic dermatitis, and lupus are caused by autoimmune responses that release numerous cytokines in the skin leading to the inflamed lesions. There are a number of biologic drugs currently approved, and a plethora of drugs in development, that target specific cytokines to mitigate the diseases. Changes in gene expression can be used to identify patients with a specific cytokine profile that may respond to a particular drug therapy. These gene expression changes can be used to monitor response to a chosen therapy and potentially predict flare-ups. We are currently developing gene expression assays to identify cytokine inflammatory profiles that assist clinicians in guiding therapy. Similar to our skin cancer products, these gene expression assays can be analyzed from samples collected using our Adhesive Skin Collection Kit. Our ResponseTNF product will help monitor patients on biologic therapy for psoriasis and help determine when a therapy changes is needed. Our CytokineEx 17 product measures the gene expression changes of the IL-17 pathway including TNF-alpha and IL-23 and can be used to facilitate drug development, as a biomarker for clinical trial endpoints, and to assess more broadly the cytokine status of patient’s skin.
An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvesting
Use of RT-PCR and DNA microarrays to characterize RNA recovered by non-invasive tape harvesting of normal and inflamed skin
Analysis of RNA recovery and gene expression in the epidermis using non-invasive tape stripping
A noninvasive method for quantifying and distinguishing inflammatory skin reactions.